144 related articles for article (PubMed ID: 10102077)
1. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. GHIS Collaborative Group.
Underwood LE; Backeljauw P; Duncan V
Acta Paediatr Suppl; 1999 Feb; 88(428):182-4. PubMed ID: 10102077
[TBL] [Abstract][Full Text] [Related]
2. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group.
Backeljauw PF; Underwood LE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3312-7. PubMed ID: 8784089
[TBL] [Abstract][Full Text] [Related]
3. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
[TBL] [Abstract][Full Text] [Related]
4. Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I).
Ranke MB
Baillieres Clin Endocrinol Metab; 1996 Jul; 10(3):401-10. PubMed ID: 8853447
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
Tonella P; Flück CE; Mullis PE
Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of insulin-like growth factor binding proteins in Ecuadorean children with growth hormone insensitivity.
Burren CP; Wanek D; Mohan S; Cohen P; Guevara-Aguirre J; Rosenfeld RG
Acta Paediatr Suppl; 1999 Feb; 88(428):185-91; discussion 192. PubMed ID: 10102078
[TBL] [Abstract][Full Text] [Related]
7. Short-term increments of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 predict the growth response to growth hormone (GH) therapy in GH-sensitive children.
Schwarze CP; Wollmann HA; Binder G; Ranke MB
Acta Paediatr Suppl; 1999 Feb; 88(428):200-8. PubMed ID: 10102080
[TBL] [Abstract][Full Text] [Related]
8. Bone density and body composition in children with growth hormone insensitivity syndrome receiving recombinant IGF-I.
Shaw NJ; Fraser NC; Rose S; Crabtree NJ; Boivin CM
Clin Endocrinol (Oxf); 2003 Oct; 59(4):487-91. PubMed ID: 14510912
[TBL] [Abstract][Full Text] [Related]
9. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
10. Laron syndrome: clinical features, molecular pathology and treatment.
Laron Z; Klinger B
Horm Res; 1994; 42(4-5):198-202. PubMed ID: 7868073
[TBL] [Abstract][Full Text] [Related]
11. Experience with insulin-like growth factor I (IGF-I) treatment of growth hormone insensitivity syndrome (GHIS).
Ranke MB; Wollmann HA; Savage MO
J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():259-66. PubMed ID: 10698590
[No Abstract] [Full Text] [Related]
12. Effects of growth hormone (GH) and insulin-like growth factor-I therapy in patients with gene defects in the GH axis.
Riedl S; Frisch H
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):229-36. PubMed ID: 16607923
[TBL] [Abstract][Full Text] [Related]
13. Phenotype: genotype relationships in growth hormone insensitivity syndrome.
Woods KA; Dastot F; Preece MA; Clark AJ; Postel-Vinay MC; Chatelain PG; Ranke MB; Rosenfeld RG; Amselem S; Savage MO
J Clin Endocrinol Metab; 1997 Nov; 82(11):3529-35. PubMed ID: 9360502
[TBL] [Abstract][Full Text] [Related]
14. Partial growth-hormone insensitivity: the role of growth-hormone receptor mutations in idiopathic short stature.
Goddard AD; Dowd P; Chernausek S; Geffner M; Gertner J; Hintz R; Hopwood N; Kaplan S; Plotnick L; Rogol A; Rosenfield R; Saenger P; Mauras N; Hershkopf R; Angulo M; Attie K
J Pediatr; 1997 Jul; 131(1 Pt 2):S51-5. PubMed ID: 9255229
[TBL] [Abstract][Full Text] [Related]
15. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.
Backeljauw PF; Underwood LE;
J Clin Endocrinol Metab; 2001 Apr; 86(4):1504-10. PubMed ID: 11297575
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone insensitivity syndrome caused by a heterozygous GHR mutation: phenotypic variability owing to moderation by nonsense-mediated decay.
Gorbenko del Blanco D; de Graaff LC; Visser TJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2012 May; 76(5):706-12. PubMed ID: 22117696
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-I (rhIGF-I) therapy of short stature.
Rosenbloom AL
J Pediatr Endocrinol Metab; 2008 Apr; 21(4):301-15. PubMed ID: 18556960
[TBL] [Abstract][Full Text] [Related]
18. Recombinant IGF-I: Past, present and future.
Bright GM
Growth Horm IGF Res; 2016 Jun; 28():62-5. PubMed ID: 26822565
[TBL] [Abstract][Full Text] [Related]
19. National Cooperative Growth Study substudy VI: the clinical utility of growth-hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements.
Attie KM; Julius JR; Stoppani C; Rundle AC
J Pediatr; 1997 Jul; 131(1 Pt 2):S56-60. PubMed ID: 9255230
[TBL] [Abstract][Full Text] [Related]
20. Partial growth hormone insensitivity--idiopathic short stature is not always idiopathic.
Saenger P
Acta Paediatr Suppl; 1999 Feb; 88(428):194-8. PubMed ID: 10102079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
